Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

Vaccine

Volumn 25, Issue 15, 2007, Pages 2787-2799

  Fogg, Christiana N ^a   Americo, Jeffrey L ^a   Lustig, Shlomo ^a   Huggins, John W ^b   Smith, Scott K ^c   Damon, Inger ^c   Resch, Wolfgang ^a   Earl, Patricia L ^a   Klinman, Dennis M ^d   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Monkeypox; Smallpox; Vaccinia virus

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; MONKEYPOX VACCINE; NEUTRALIZING ANTIBODY; PROTEIN A33; PROTEIN B5; PROTEIN L1; PROTEIN QS 21; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; MONKEY; MONKEYPOX VIRUS; MORBIDITY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; SKIN DEFECT; VACCINIA VIRUS; VIRUS INFECTION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; FEMALE; HELA CELLS; HUMANS; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MONKEYPOX VIRUS; OLIGONUCLEOTIDES; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; SAPONINS; VACCINIA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 33947170378     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.037     Document Type: Article

References (63)

1. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its eradication. 1st ed. (1988), World Health Organization, Geneva
2. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., and Henderson D.A. Smallpox vaccination: a review, part II. Adverse events. Clin Inf Dis 37 July (2) (2003) 251-271
3. Henderson D.A. The looming threat of bioterrorism. Science 283 February (5406) (1999) 1279-1282
4. Moss B. Poxviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 2849-2883
5. Boulter E.A., Zwartouw H.T., Titmuss D.H.J., and Maber H.B. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol 94 (1971) 612-620
6. Boulter E.A., and Appleyard G. Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol 16 (1973) 86-108
7. Law M., Putz M.M., and Smith G.L. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 86 April (Pt 4) (2005) 991-1000
8. Payne L.G. Significance of extracellular virus in the in vitro and in vivo dissemination of vaccinia virus. J Gen Virol 50 (1980) 89-100
9. Blasco R., and Moss B. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol 66 7 (1992) 4170-4179
10. Smith G.L., Vanderplasschen A., and Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83 December (Pt 12) (2002) 2915-2931
11. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78 October (19) (2004) 10230-10237
12. Lai C.F., Gong S.C., and Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 65 10 (1991) 5631-5635
13. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y.X., et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79 September (18) (2005) 11724-11733
14. Galmiche M.C., Goenaga J., Wittek R., and Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254 1 (1999) 71-80
15. Fang M., Cheng H., Dai Z.P., Bu Z.M., and Sigal L.J. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345 February (1) (2006) 231-243
16. Hooper J.W., Custer D.M., and Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306 February (1) (2003) 181-195
17. Heraud J.M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 177 August (4) (2006) 2552-2564
18. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 79 (2005) 13454-13462
19. Chen Z.C., Earl P., Americo J., Damon I., Smith S.K., Zhou Y.H., et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 103 February (6) (2006) 1882-1887
20. Poltorak A., Smirnova I., He X., Liu M.Y., Van Huffel C., McNally O., et al. Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 24 September (3) (1998) 340-355
21. Takayama K., Ribi E., and Cantrell J.L. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res 41 July (7) (1981) 2654-2657
22. Masihi K.N., Lange W., Brehmer W., and Ribi E. Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int J Immunopharmacol 8 3 (1986) 339-345
23. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., and Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2 April (2) (2003) 219-229
24. Liu G., Anderson C., Scaltreto H., Barbon J., and Kensil C.R. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine 20 21-22 (2002) 2808-2815
25. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19 February (15-16) (2001) 2080-2091
26. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R., Newman M.J., et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12 November (14) (1994) 1275-1280
27. Kashala O., Amador R., Valero M.V., Moreno A., Barbosa A., Nickel B., et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 20 May (17-18) (2002) 2263-2277
28. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93 April (7) (1996) 2879-2883
29. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 April (6522) (1995) 546-549
30. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., Kataoka T., et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36 9 (1992) 983-997
31. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 April (4) (2004) 249-258
32. Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: Gregoriadis G.A., and Poste A.G. (Eds). NATO Advanced Study Institute on Immunological Adjuvants and Vaccines (1988), Plenum Press, New York 35-41
33. Jordan M.B., Mills D.M., Kappler J., Marrack P., and Cambier J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304 June (5678) (2004) 1808-1810
34. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 October (5) (2004) 497-505
35. Turner G.S. Respiratory infection of mice with vaccinia virus. J Gen Virol 1 3 (1967) 399-402
36. Williamson J.D., Reith R.W., Jeffrey L.J., Arrand J.R., and Mackett M. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71 November (1990) 2761-2767
37. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 (2004) 182-185
38. Anton L.C., Schubert U., Bacik I., Princiotta M.F., Wearsch P.A., Gibbs J., et al. Intracellular localization of proteasomal degradation of a viral antigen. J Cell Biol 146 July (1) (1999) 113-124
39. Norbury C.C., Malide D., Gibbs J.S., Bennink J.R., and Yewdell J.W. Visualizing priming of virus-specific CD8(+) T cells by infected dendritic cells in vivo. Nat Immunol 3 March (3) (2002) 265-271
40. Earl P.L., Cooper N., Wyatt S., Moss B., and Carroll M.W. Preparation of cell cultures and vaccinia virus stocks. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., et al. (Eds). Current protocols in molecular biology (1998), John Wiley and Sons, New York 16.16.1-16.16.3
41. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Hirao L., Isaacs S.N., et al. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol 79 May (10) (2005) 6260-6271
42. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Pannell L.K., Lebowitz J., et al. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341 1 (2005) 59-71
43. Earl P.L., Americo J.L., and Moss B. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 77 October (19) (2003) 10684-10688
44. Yang H.L., Kim S.K., Kim M., Reche P.A., Morehead T.J., Damon I.K., et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 115 February (2) (2005) 379-387
45. Journot V., Chene G., Joly P., Saves M., Jacqmin-Gadda H., Molina J.M., et al. Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods. Control Clin Trials 22 December (6) (2001) 639-658
46. Holm S. A simple sequentialrejective multiple test procedure. Scand J Stat 6 (1979) 65-70
47. Luker K.E., Hutchens M., Schultz T., Pekosz A., and Luker G.D. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341 October (2) (2005) 284-300
48. Rees D.G.C., Gates A.J., Green M., Eastaugh L., Lukaszewski R.A., Griffin K.F., et al. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res 65 February (2) (2005) 87-95
49. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 August (16) (2003) 9458-9463
50. Xu R., Johnson A.J., Liggitt D., and Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 172 May (10) (2004) 6265-6271
51. Wyatt L.S., Earl P.L., Eller L.A., and Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Nat Acad Sci USA 101 (2004) 4590-4595
52. Panchanathan V., Chaudhri G., and Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc Natl Acad Sci USA 102 September (36) (2005) 12921-12926
53. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11 July (7) (2005) 740-747
54. Mikloska Z., Ruckholdt M., Ghadiminejad I., Dunckley H., Denis M., and Cunningham A.L. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 164 May (10) (2000) 5167-5176
55. Moore A., McCarthy L., and Mills K.H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17 June (20-21) (1999) 2517-2527
56. Newman M.J., Wu J.Y., Gardner B.H., Munroe K.J., Leombruno D., Recchia J., et al. Saponin adjuvant induction of ovalbumin-specific CD8 + cytotoxic T lymphocyte responses. J Immunol 148 April (8) (1992) 2357-2562
57. Wu J.Y., Gardner B.H., Murphy C.I., Seals J.R., Kensil C.R., Recchia J., et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol 148 March (5) (1992) 1519-1525
58. Newman M.J., Munroe K.J., Anderson C.A., Murphy C.I., Panicali D.L., Seals J.R., et al. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Res Hum Retroviruses 10 July (7) (1994) 853-861
59. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., and Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160 January (2) (1998) 870-876
60. Oxenius A., Martinic M.M., Hengartner H., and Klenerman P. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol 73 May (5) (1999) 4120-4126
61. Bell E., Shamim M., Whitbeck J.C., Sfyroera G., Lambris J.D., and Isaacs S.N. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325 August (2) (2004) 425-431
62. Earl P.L., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 75 2 (2001) 645-653
63. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78 9 (2004) 4433-4443